Shionogi expands allergy interests with nucleic acid therapy deal
This article was originally published in Scrip
Executive Summary
Shionogi has added to its existing limited presence in the allergy area with the acquisition of exclusive global rights to AnGes MG's pipeline nuclear factor-kappa B decoy oligodeoxynucleotide therapy for the treatment of atopic dermatitis and other skin disorders.